LeMaitre Vascular (NASDAQ:LMAT) Issues Q2 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its second quarter 2024 earnings guidance on Friday morning. The company provided EPS guidance of 0.450-0.500 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $53.7 million-$56.1 million, compared to the consensus revenue estimate of $54.3 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.730-1.840 EPS.

LeMaitre Vascular Trading Up 11.2 %

LMAT stock opened at $74.22 on Monday. The firm has a 50-day moving average price of $65.93 and a 200-day moving average price of $58.85. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64. The stock has a market capitalization of $1.67 billion, a P/E ratio of 49.15, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. As a group, equities analysts predict that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. KeyCorp assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a sector weight rating for the company. JMP Securities raised their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research report on Friday. Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and raised their price objective for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Barrington Research raised their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research report on Friday. Finally, StockNews.com upgraded shares of LeMaitre Vascular from a hold rating to a buy rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $73.83.

Insider Transactions at LeMaitre Vascular

In related news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the sale, the director now directly owns 5,309 shares in the company, valued at $358,357.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of LeMaitre Vascular stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the completion of the sale, the chief financial officer now directly owns 6,452 shares in the company, valued at approximately $450,091.52. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock worth $7,873,749 in the last 90 days. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.